{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:19Z","timestamp":1792719859449,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011033.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000}}],"reference-count":51,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011033.pub4","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T14:34:35Z","timestamp":1588602875000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacological treatment for Buerger's disease"],"prefix":"10.1002","author":[{"given":"Daniel G","family":"Cacione","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, Department of Surgery; UNIFESP - Escola Paulista de Medicina; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane R","family":"Macedo","sequence":"additional","affiliation":[{"name":"Brazilian Cochrane Centre; Centro de Estudos de Sa\u00fade Baseada em Evid\u00eancias e Avalia\u00e7\u00e3o Tecnol\u00f3gica em Sa\u00fade; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico","family":"do Carmo Novaes","sequence":"additional","affiliation":[{"name":"Department of Surgery; UNIFESP - Escola Paulista de Medicina; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose CC","family":"Baptista-Silva","sequence":"additional","affiliation":[{"name":"Evidence Based Medicine, Cochrane Brazil; Universidade Federal de S\u00e3o Paulo; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"10.1002\/14651858.CD011033.pub4-BIB0001|cit1","first-page":"1034","article-title":"The role of folic acid on the hyperhomocysteinemia in the Buerger's disease (thromboangiitis obliterans)","volume":"19","author":"Beigi","year":"2014","journal-title":"Journal of Research in Medical Sciences"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0002|cit2","first-page":"2111","article-title":"Studies on the clinical efficacy and safety of TTC-909 in the treatment of peripheral arterial occlusive disease: a multi-center double-blind comparison with Alprostadil incorporated in lipid microspheres","volume":"11","author":"Esato","year":"1995","journal-title":"Rinsho Iyaku"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0003|cit3","first-page":"178","article-title":"Multicenter-study on Iloprost in patients with thromboangiitis obliterans (Buerger's disease)","volume":"67","author":"Diehm","year":"1989","journal-title":"Klinische Wochenschrift"},{"issue":"8689","key":"10.1002\/14651858.CD011033.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0140-6736(90)90346-7","article-title":"Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans","volume":"335","author":"Fiessinger","year":"1990","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0005|cit5","first-page":"1836","article-title":"Therapeutic efficacy of iloprost, a prostacyclin analogue for chronic arterial occlusion: a double-blind comparative study with PGE1","volume":"68","author":"Ishitobi","year":"1991","journal-title":"Rinsho to Kenkyu"},{"issue":"4","key":"10.1002\/14651858.CD011033.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1078-5884(98)80032-4","article-title":"Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group","volume":"15","author":"Verstraete","year":"1998","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0007|cit7","first-page":"162","article-title":"A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease","volume":"25","author":"Bozkurt","year":"2006","journal-title":"International Angiology"},{"issue":"9","key":"10.1002\/14651858.CD011033.pub4-BIB0008|cit8","first-page":"497","article-title":"Effects of nicergoline in peripheral arteriopathies of the lower limbs. Double-blind study","volume":"20","author":"Coscia","year":"1972","journal-title":"Minerva Cardioangiologica"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0009|cit9","first-page":"76","article-title":"The application of Simiaoyongantangjiawei in the treatment of thromboangiitis obliterans","volume":"14","author":"He","year":"2007","journal-title":"Chinese Journal of Information on Traditional Chinese Medicine"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0010|cit10","first-page":"3409","article-title":"Results of dose finding study of Pamicogrel (KBT-3022) on chronic arterial occlusive diseases","volume":"13","author":"Hoshino","year":"1997","journal-title":"Rinsho Iyaku"},{"issue":"1","key":"10.1002\/14651858.CD011033.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0090-6980(86)90225-X","article-title":"Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease","volume":"31","author":"Musial","year":"1986","journal-title":"Prostaglandins"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/cpt1975175612","article-title":"Controlled trial of propranolol in intermittent claudication","volume":"17","author":"Reichert","year":"1975","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0013|cit13","first-page":"2025","article-title":"Report on the clinical testing of Lamuran (I)","volume":"35","author":"Steinorth","year":"1967","journal-title":"Die Medizinische Welt"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0014|cit14","first-page":"10","article-title":"Point injection of prostaglandin E1 on Sanyinjiao Acupuncture (SP6) for thromboangiitis obliterans pain in 24 cases","volume":"13","author":"Sun","year":"1993","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0015|cit15","first-page":"73","article-title":"Clinical study of treating thromboangitis obliterans with overlapping thinning chisel therapy","volume":"12","author":"Yang","year":"2005","journal-title":"Chinese Journal of Information on TCM"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1536\/ihj.14.12","article-title":"A clinical trial with pyridinolcarbamate in the treatment of patients with obstructive diseases of the peripheral arteries","volume":"14","author":"Zelikovsky","year":"1973","journal-title":"Japanese Heart Journal"},{"issue":"7454","key":"10.1002\/14651858.CD011033.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011033.pub4-BIB0018|cit18","first-page":"82","article-title":"Buerger's disease: etiologic role of the rickettsiae?","volume":"12","author":"Bartolo","year":"1987","journal-title":"Journal des Maladies Vasculaires"},{"issue":"10","key":"10.1002\/14651858.CD011033.pub4-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003748.pub4","article-title":"Cilostazol for intermittent claudication","author":"Bedenis","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0020|cit20","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","author":"Brunton","year":"2011"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00000441-190810000-00011","article-title":"Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene","volume":"136","author":"Buerger","year":"1908","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0022|cit22","first-page":"31","volume-title":"Thromboangiitis obliterans Morbus Winiwarter-Buerger","author":"Cachovan","year":"1988"},{"issue":"2","key":"10.1002\/14651858.CD011033.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00129784-200303020-00006","article-title":"Cilostazol: a review of its use in intermittent claudication","volume":"3","author":"Chapman","year":"2003","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"12","key":"10.1002\/14651858.CD011033.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.jacc.2004.09.029","article-title":"Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease)","volume":"44","author":"Cooper","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"De Haro J Florez A Fernadez JL Acin F Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report BMJ Case Reports 2009 10.1136\/bcr.08.2008.0691","DOI":"10.1136\/bcr.08.2008.0691"},{"issue":"1","key":"10.1002\/14651858.CD011033.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/157489009787260025","article-title":"A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy","volume":"4","author":"Dindyal","year":"2009","journal-title":"Recent Patents on Cardiovascular Drug Discovery"},{"issue":"5","key":"10.1002\/14651858.CD011033.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/1708538113491256","article-title":"Is rickettsia the key to solving the puzzle of Buerger\u2019s disease?","volume":"22","author":"Fazeli","year":"2013","journal-title":"Vascular"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0028|cit28","unstructured":"FDA approved drug products \/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search. DrugDetails"},{"issue":"5\/6","key":"10.1002\/14651858.CD011033.pub4-BIB0029|cit29","first-page":"499","article-title":"Surgical treatment of peripheral circulation disorders","volume":"21","author":"Fontaine","year":"1954","journal-title":"Helvetica Chirurgica Acta"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0030|cit30","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"issue":"6","key":"10.1002\/14651858.CD011033.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199243060-00008","article-title":"Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0032|cit32","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011033.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jvs.2005.03.016","article-title":"Oral bacteria in the occluded arteries of patients with Buerger disease","volume":"42","author":"Iwai","year":"2005","journal-title":"Journal of Vascular Surgery"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD011033.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0755-4982(06)74645-0","article-title":"Bosentan for treatment of active digital ulcers in patients with systemic sclerosis","volume":"35","author":"Launay","year":"2006","journal-title":"La Presse M\u00e9dicale"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0035|cit35","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD011033.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.thromres.2008.03.011","article-title":"An ultrastructural study of Porphyromonas gingivalis-induced platelet aggregation","volume":"122","author":"Li","year":"2008","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1002\/14651858.CD011033.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2009.01.042","article-title":"Thromboangiitis obliterans in the 21st century - a new face of disease","volume":"206","author":"Malecki","year":"2009","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD011033.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD011033.pub4-BIB0039|cit39","first-page":"219","article-title":"Critical limb ischemia: definition and natural history","volume":"4","author":"Novo","year":"2004","journal-title":"Current Drug Targets"},{"issue":"12","key":"10.1002\/14651858.CD011033.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJM200009213431207","article-title":"Thromboangiitis obliterans (Buerger's disease)","volume":"343","author":"Olin","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011033.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.bor.0000198000.58073.aa","article-title":"Thromboangiitis obliterans (Buerger\u2019s disease)","volume":"18","author":"Olin","year":"2006","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0042|cit42","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"1","key":"10.1002\/14651858.CD011033.pub4-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006544.pub2","article-title":"Prostanoids for critical limb ischaemia","author":"Ruffolo","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0044|cit44","volume-title":"Vascular Surgery","volume":"1","author":"Rutherford","year":"2005"},{"issue":"6","key":"10.1002\/14651858.CD011033.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.rmed.2010.12.018","article-title":"Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs","volume":"105","author":"Safdar","year":"2011","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011033.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/BF01655948","article-title":"What is Buerger's disease?","volume":"7","author":"Shionoya","year":"1983","journal-title":"World Journal of Surgery"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0047|cit47","first-page":"202","article-title":"A peculiar form of endarteritis and endophlebitis with gangrene of the foot","volume":"23","author":"Winiwarter","year":"1879","journal-title":"Archiv f\u00fcr Klinische Chirurgie"},{"key":"10.1002\/14651858.CD011033.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0009-9236(96)90127-7","article-title":"Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentanin healthy human subjects","volume":"60","author":"Weber","year":"1996","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD011033.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCULATIONAHA.111.060335","article-title":"Nonatherosclerotic arterial disorders of the lower extremities","volume":"126","author":"Weinberg","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD011033.pub4-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011033","article-title":"Pharmacological treatment for Buerger's disease","author":"Cacione","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011033.pub4-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011033.pub3","article-title":"Pharmacological treatment for Buerger's disease","author":"Cacione","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:51:42Z","timestamp":1628549502000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD011033.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011033.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]}}}